



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

22 March 2019  
EMA/CVMP/164096/2019  
Committee for Medicinal Products for Veterinary Use

### Summary of opinion<sup>1</sup> (post-authorisation)

---

## Vectra 3D

International non-proprietary name (INN): dinotefuran / pyriproxyfen / permethrin

On 21 March 2019, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Vectra 3D. The marketing authorisation holder for this veterinary medicinal product is CEVA Santé Animale.

Vectra 3D is currently authorised in dogs as spot-on solution for the treatment and prevention of flea, tick, sand fly, mosquito and stable fly infestations. The variation concerns the change of legal status from prescription-only to non-prescription veterinary medicine.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

---

<sup>1</sup> Summaries of opinion are published without prejudice to the Commission Decision.

